In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

“Weight-loss methods, whether with pharmacotherapy or surgery, have to be mindful to avoid inducing these complications,” ...

Cholestatic liver diseases comprise a heterogeneous group of disorders characterized by impaired bile formation or flow, ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Right now, patients with obesity and cirrhosis ...

New data links the liver receptor GPR110 to sex-specific progression of metabolic dysfunction-associated steatohepatitis.

People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Steatotic liver disease (commonly called fatty liver disease) progresses silently. Even in the absence of noticeable symptoms ...

New analysis shows alcohol-related liver disease remains a major cause of cirrhosis and liver death. Read more.